KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables (2016 - 2025)

Historic Receivables for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $177.6 million.

  • Supernus Pharmaceuticals' Receivables rose 2210.74% to $177.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.6 million, marking a year-over-year increase of 2210.74%. This contributed to the annual value of $146.1 million for FY2024, which is 133.33% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Receivables of $177.6 million as of Q3 2025, which was up 2210.74% from $146.2 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Receivables registered a high of $177.6 million during Q3 2025, and its lowest value of $127.1 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables was $145.6 million (2025), whereas its average is $147.7 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Receivables skyrocketed by 2274.9% in 2022, and later tumbled by 1360.66% in 2023.
  • Supernus Pharmaceuticals' Receivables (Quarter) stood at $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then dropped by 12.9% to $144.2 million in 2023, then increased by 1.33% to $146.1 million in 2024, then increased by 21.55% to $177.6 million in 2025.
  • Its Receivables was $177.6 million in Q3 2025, compared to $146.2 million in Q2 2025 and $145.6 million in Q1 2025.